Company Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease.
It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite.
Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 2, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Esther Rajavelu |
Contact Details
Address: 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 United States | |
| Phone | (857) 242-1600 |
| Website | sperotherapeutics.com |
Stock Details
| Ticker Symbol | SPRO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001701108 |
| CUSIP Number | 84833T103 |
| ISIN Number | US84833T1034 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Esther P. Rajavelu | Interim President, Interim Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer |
| Dr. Ankit Mahadevia M.D., MBA | Co-Founder and Director |
| Timothy Keutzer | Chief Operating Officer |
| James P. Brady | Chief Human Resource Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | SCHEDULE 13D/A | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Feb 28, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Sep 10, 2024 | 8-K | Current Report |